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Background: It has been recognized that reduction of abdominal visceral fat and subcutaneous fat are associated
with improvement in insulin-resistance (IR) after weight loss. However, few studies have investigated the correlation
of reduction in epicardial adipose tissue (EAT) with improvement of IR index after weight loss in obese non-diabetic
men with metabolic syndrome (MetS).
Methods and results: We prospectively enrolled 32 non-diabetic men with MetS for a 3-month weight reduction
program mainly by diet control and exercise. Magnetic resonance imaging (MRI) examinations were used to measure
EAT, subcutaneous fat, and abdominal visceral fat. Anthropometric parameters, oral glucose tolerance test (OGTT), and
serum adipokines were assessed before and after the weight loss program. After a 3-month weight loss program, 27
obese MetS men had significant weight loss >5% (97 ± 14 to 87 ± 14 kg, with a 10.7 % decrease, p < 0.001). Multivariate
analysis revealed that the decrement ratio of superior interventricular groove (SIVG) EAT thickness (r = 0.322, p = 0.044)
and serum leptin (r = 0.626, p < 0.001) significantly correlated with the percentage improvements of fasting HOMA-IR
index. Furthermore, the decrement ratio of SIVG EAT thickness (r = −0.370, p = 0.017) and decrement ratio of
subcutaneous fat area (r = −0.673, p = 0.006) were significantly correlated with improvement of OGTT-derived
Matsuda insulin-sensitivity index.
Conclusions: The decrement ratio of SIVG EAT correlated with improvement of both HOMA-IR and OGTT-derived
Matsuda insulin-sensitivity indexes after weight loss in obese non-diabetic men with MetS.
Clinical trial registration: (Multi-faceted Evaluations Following Weight Reduction in Subjects with Metabolic
Syndrome NCT 01065753 on Feb 8, 2010).
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The core pathogenesis of metabolic syndrome (MetS) is
related to obesity and insulin resistance (IR) [1]. MetS is
associated with a higher incidence of cardiovascular dis-
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unless otherwise stated.[2-5]. We and others have demonstrated that victims of
MetS manifest a pro-thrombotic and pro-inflammatory
state [6-8]. Even in subjects without type 2 diabetes mel-
litus, MetS alone still carries a 1.6-fold increased risk of
myocardial infarction and a 1.8-fold increased risk of
cardiovascular mortality [5].
Epicardial adipose tissue (EAT) is a part of visceral fat
deposited around the heart between the pericardium and
myocardium [9]. The distribution of EAT is asymmetric
and mostly localizes at perivascular, interventricular, and
atrioventricular grooves [10,11]. Animal study showedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study enrollment and protocol. MRI: magnetic
resonance imaging.
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cantly higher in EAT compared with other fat depots [12].
In addition to storing lipids, it also produces inflammatory
cytokines and adipokines [9,13,14]. Measurements of EAT
by computed tomography (CT) or echocardiogram have
been used for predicting components of MetS or coronary
atherosclerosis severity [15-18]. Some studies have ad-
dressed the possible mechanism of EAT in coronary ath-
erosclerosis, such as an increase of local EAT leptin [19]
and inflammatory cytokine secretion [13], or a decrease of
adiponectin production [14], which might directly be dif-
fused into adjacent coronary circulation and influence ath-
erosclerosis [10]. In fact, it has been shown that leptin
expression was higher in EAT obtained from subjects with
MetS or coronary heart disease [19,20]. However, whether
total EAT volume [16,21], average EAT thickness [22] or
regional EAT thickness [15,18] better predicts coronary
atherosclerosis or MetS is still under debate and whether
there is a regional specific EAT difference in atherogenesis
is still inconclusive [10]. Recently, we reported that differ-
ences in right atrio-ventricular groove EAT thickness can
help differentiate the inflammatory status of obese non-
diabetic men with MetS [23].
Weight loss improves IR, decreases circulating leptin
and increases adiponectin in obesity or MetS [24-26].
There have been inconsistent reports whether reduction
of abdominal visceral fat or subcutaneous fat is better
correlated with the improvement of IR after weight loss
[27-31]. In addition, few studies have investigated the
correlations of reductions of regional EAT with improve-
ment of IR after weight loss in obesity or MetS. More-
over, alterations of circulating adipokine change and
improvement of IR following weight loss in obese non-
diabetic men with MetS was largely unexplored. The
aims of this study were to elucidate the correlations of
regional EAT thickness changes by magnetic resonance
imaging (MRI) with improvement of IR and changes in




We prospectively enrolled 40 men in total, who were di-
agnosed with MetS using the ATP-III criteria, from out-
patient clinics at Taichung Veterans General Hospital
(Taichung, Taiwan) in April to September 2008 (Figure 1).
Parts of the results have been published previously
[23,25,26]. In brief, the study enrollment criteria included
central obesity, which was defined as waist circumfer-
ence ≥90 cm, in addition to at least two other ATP-III
MetS criteria [32]. Patients with diabetes mellitus requir-
ing oral anti-diabetic agents or insulin shots were ex-
cluded from the study. The patients undertook a 3-month
weight reduction program. The dietitian instructed thestudy subjects to consume a 1200 Kcal diet per day
comprising 55% carbohydrate, 30% fat, and 15% protein.
Patients were educated how to estimate the calories and
nutritional components per unit amount of food [25,33,34].
They all received an instruction brochure, which stated
all the nutritional facts and calories per unit amount
of food for instant check. The patients were asked to
keep a very detailed record of each meal. A dietitian
would estimate the calories based on the record in order
to keep the daily requirement of 1200Kcal per day. In
addition, the dietitian closely followed them with phone-
call consultations. We encouraged peer competition for
weight loss and showed weight and waist circumfer-
ence changes in bar graphs at each gathering, which
was held once every week in the first month, then bi-
weekly in the 2nd and 3rd month. The patients were
encouraged to have at least two to three light physical
exercise periods per week. We provided a 60-minute
fitness program with a physical trainer at the biweekly
gatherings. The study subjects underwent anthropo-
metric data check and blood sampling again at the
3rd, 12th and 18th month after the beginning of weight
loss program and then every 24 months thereafter if
they are compliant with our recalls. Thirty-two of the
obese non-diabetic men with MetS agreed undergoing
MRI examination for measurement of subcutaneous fat,
abdominal visceral fat, and EAT before and after weight
loss (Figure 1). All subjects provided written informed
consent. The authors confirm that all ongoing and re-
lated trials for this study/intervention are registered.
The study protocol was approved by the Human Research
Ethics Review Committee of Taichung Veterans General
Hospital (Taichung, Taiwan). The protocol and case
enrollment were conducted after getting the ethics
committee approval; however, the registration at www.
clinicaltrials.gov (Multi-faceted Evaluations Following
Weight Reduction in Subjects with Metabolic Syndrome
NCT 01065753) was delayed till Feb 8, 2010 because clin-
ical trial registration was not compulsory in our country
back then.
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All obese MetS subjects underwent blood tests and oral
glucose tolerance test (OGTT) after an overnight fast to ex-
clude those with unknown diabetes. After a fasting blood
sample was collected, glucose load of 75 g was ingested
over 5 minutes. Blood samples were collected at 30 minutes,
60 minutes, 90 minutes, and 120 minutes after the test
load. Blood glucose and insulin concentrations were mea-
sured in each sample. Serum insulin was determined by a
commercially available assay kit (IMMULITE, I-2000,
EURO/Diagnostic Products Corporation, Gwynedd, UK).
The inter- and intra-assay coefficients of variation for
insulin (range 10.7 to 439 μU/ml) were 4.3% and 5.4%,
respectively. Insulin-resistance was estimated using the
homeostasis model assessment of IR (HOMA-IR), defined
as fasting glucose mg/dl × fasting insulin μU/mL/405
[35,36]. OGTT-derived Matsuda insulin-sensitivity index
(ISI) was defined as 10,000/sqrt [fasting glucose (mM) ×
fasting insulin (μU/mL) × mean glucose during OGTT
(mM) × mean insulin during OGTT (μU/mL)] [37].
OGTT glucose and insulin areas under the curve (AUC)
were defined as areas under the curve for glucose and in-
sulin vs. time during the OGTT, respectively [8]. Serum
hs-CRP was determined by particle-enhanced immuno-
turbidimetry (Latex microparticles sensitized with duck
anti-CRP IgY kit, provided by Good Biotech Corp.,
Taichung, Taiwan). The intra- and inter-assay coefficients
of variance were 1.4% and 1.42%, respectively [8]. Serum
monocyte chemotactic protein (MCP)-1 was determined
by enzyme-linked immunosorbent assays (R&D Systems,
Inc., Minneapolis, MN, USA) [38,39]. The intra- and
inter-assay coefficients of variation for MCP-1 were 5.80%
and 5.70%, respectively, with a minimum detectable con-
centration of <5.0 pg/mL.
Measurement of circulating adipokines
Serum adiponectin, leptin, and plasma plasminogen activa-
tor inhibitor (PAI)-1 concentrations were determined by
enzyme-linked immunosorbent assays (R&D Systems, Inc.,
Minneapolis, MN, USA). The intra-assay and inter-assay
coefficients of variation of PAI-1 were 6.73% and 7.33%, re-
spectively, with a minimum detectable concentration of
0.014-0.142 ng/mL. The intra- and inter-assay coefficients
of variation for adiponectin were 3.53% and 6.50%, respect-
ively, with a minimum detectable concentration of 0.079-
0.891 ng/mL. The intra- and inter-assay coefficients of
variation for leptin were 3.17% and 4.37%, respectively,
with a minimum detectable concentration of <7.8 pg/mL.
MRI examination for subcutaneous fat, abdominal visceral
fat, and EAT
Subcutaneous fat and abdominal visceral fat areas were
quantified using MRI. Data were acquired using a 1.5 T
whole body Siemens Sonata system (Siemens MedicalSystems, Erlangen, Germany) using the body coil. For
the quantification of abdominal fat, one axial slice of the
abdomen was obtained at the level of umbilicus. The
scan parameters used were TR =209 ms, TE =4.1 ms, slice
thickness =10 mm, and flip angle =70°. The field of view
was 400 mm with an in-plane image resolution of 2.4 mm×
1.6 mm [40]. Areas of abdominal visceral fat and subcuta-
neous fat (millimeters squared) were measured on the
computer screen using a track-ball [41]. All measurements
were analyzed by a single radiologist who was blinded to
the metabolic status of the study subjects.
For EAT measurement, electrocardiogram-gated cine im-
ages were acquired with a dedicated 4-element, phased array
cardiac coil, using a segmented steady-state free precession
[fast imaging with steady-state precession (TrueFISP)]
sequence (time to echo/time of repetition 1.6/3.2 ms,
temporal resolution 35 ms, in-plane spatial resolution
1.4*1.8 mm, slice thickness 5 mm, inter-slice gap 5 mm).
The measurements were done in end-diastolic phase on
horizontal long-axis plane and basal short-axis plane (at
the level of the end of papillary muscles). Fat thickness in
right atrioventricular groove, left atrioventricular groove,
and anterior interventricular groove were measured on
horizontal long-axis plane; fat thickness in superior inter-
ventricular groove, inferior interventricular groove and
right ventricular free wall were measured on basal short-
axis plane, as described in our previous studies and by
other investigators [15,23,26,42].
Statistical analysis
Continuous variables are expressed as mean ± S.D. Dif-
ferences in continuous variables before and after weight
loss in obese MetS subjects were compared by the paired
Student’s t test. Univariate correlation analysis between
percentage changes of HOMA-IR or ISI-Matsuda after
weight loss vs. percentage changes of obesity-associated
inflammatory markers, adipokines, and MRI-measured
fat index in obese MetS were analyzed using Pearson
correlation analysis. Multivariate linear regression analysis
was performed to investigate the independent variables
correlated with percentage changes of HOMA-IR or ISI-
Matsuda after weight loss. The SPSS 17.0 statistical soft-
ware package (SPSS, Inc., Chicago, IL, USA) was used for
all calculations. A two-tailed p value less than 0.05 was
considered statistically significant.
Results
Changes in anthropometric, serum or plasma biochemical
data, and adipokines after weight loss
After the 3-month weight reduction program, twenty-
seven of the obese non-diabetic men with MetS achieved
weight loss of more than 5% (97 ± 14 to 87 ± 14 kg, with
an average decrease of 10.7%, p < 0.001) (Figure 1). The
fasting HOMA-IR, OGTT-derived Matsuda ISI, and OGTT
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loss (Table 1). Lipid profiles improved and inflammatory
markers such as MCP-1 declined after weight loss
(Table 1). In terms of circulating adipokines, the obese
non-diabetic men had significantly lower values of PAI-1
after weight loss. There were non-significant changes of
adiponectin and leptin levels after weight loss (Table 1).
Changes of MRI measured subcutaneous fat, abdominal
visceral fat, and regional thickness of EAT in obese
non-diabetic men with MetS after weight loss
Significant reductions of subcutaneous fat and abdom-
inal visceral fat areas as well as decreases of regional
EAT thickness were detected in the 27 obese men who
achieved significant weight loss (all p < 0.001) (Table 2).
Univariate correlation analysis of percentage changes in
HOMA-IR index with obesity-associated inflammatory
markers, adipokines, and MRI-measured fat index after
weight loss
The percentage improvements in HOMA- IR index after
weight loss were significantly correlated with the MRI-Table 1 Changes of anthropometric, serum or plasma biochem
metabolic syndrome with weight loss >5% (N = 27) by diet an
Before
Body weight (kg) 97
BMI (kg/m2) 33.5
Fasting glucose (mg/dl) 103
Fasting insulin (μIU/ml) 18.6
HOMA-IR (mg/dl × μIU/ml) 4.8
OGTT glucose AUC (mg/dl × h) 367
OGTT insulin AUC (μIU/ml × h) 200
OGTT derived insulin-sensitivity index, Matsuda (mM × μIU/ml)−1 40.6









BMI (kg/m2): body mass index = body weight (kg)/height2 (m).
HDL-C: high-density-lipoprotein cholesterol.
HOMA-IR: homeostasis model assessment (HOMA) index of insulin resistance = (fast
MCP-1: monocyte chemotactic protein-1.
MetS: metabolic syndrome.
OGTT glucose AUC: oral glucose tolerance test, area under the curve for glucose.
OGTT insulin AUC: oral glucose tolerance test, area under the curve for insulin.
OGTT insulin-sensitivity index (Matsuda): 10,000⁄sqrt (FBG × FPI × G × I) where FPG
I is mean insulin (μIU/ml) during the OGTT.
PAI-1: plasminogen activator inhibitor-1.
*Percentage of changes = (after - before)/before weight loss, mean value.measured decrement ratio of superior interventricular
groove (SIVG) EAT thickness (r =0.408, p = 0.035), but
not with the subcutaneous fat or abdominal visceral fat
changes (Table 3). Moreover, the percentage improvement
of HOMA-IR index was also significantly correlated
with decrement ratio of secretory leptin after weight loss
(r = 0.685, p < 0.001) (Table 3).
Univariate correlation analysis of percentage changes in
OGTT-derived Matsuda insulin-sensitivity index with
obesity-associated inflammatory markers, adipokines, and
MRI-measured fat index after weight loss
The percentage improvements of OGTT-derived Matsuda
ISI were significantly correlated with MRI-measured decre-
ment ratio of SIVG EAT thickness (r = −0.501, p = 0.008)
as well as with the subcutaneous fat (r = −0.642, p < 0.001),
but not with abdominal visceral fat changes after weight
loss (Table 3). Moreover, the percentage improvement of
OGTT-derived Matsuda ISI was also significantly corre-
lated with decrement ratio of secretory leptin after weight
loss (r = −0.439, p = 0.022) (Table 3). In a separate analysis,
the decrement ratio of SIVG EAT also correlated well withical data and adipokines in obese non-diabetic men with
d exercise program
(N = 27) After (N = 27) *Percentage of changes P value
± 14 87 ± 14 −10.7% <0.001
± 4.1 29.9 ± 4.2 −10.6% <0.001
± 15 97 ± 10 −5.7% 0.002
± 12.1 13.0 ± 7.3 −25.8% 0.005
± 3.2 3.1 ± 1.7 −29.5% 0.003
± 79 324 ± 55 −9.8% <0.001
± 99 148 ± 75 −21.1% 0.002
± 16.6 64.6 ± 31.2 69.7% <0.001
± 51 187 ± 35 −7.2% 0.011
± 9 44 ± 10 11.2% 0.021
± 515 174 ± 294 −36.6% 0.012
± 88 215 ± 66 −19.5% <0.001
± 0.41 0.14 ± 0.11 −19.3% 0.061
± 1803 3377 ± 2140 35.5% 0.431
± 9932 11673 ± 11362 −21.2% 0.067
± 8.2 9.7 ± 4.9 −37.0% <0.001
ing glucose mg/dl × fasting insulin μU/mL)/405.
is fasting glucose (mM), FPI is fasting insulin (μIU/ml), G is mean glucose (mM),
Table 2 Changes of MRI measured subcutaneous fat, abdominal visceral fat, and regional thickness of epicardial
adipose tissue in obese non-diabetic men with metabolic syndrome with weight loss >5% (N = 27)
Before (N = 27) After (N = 27) *Percentage of changes P value
Waist (cm) 122.6 ± 10.0 112.8 ± 11.4 −8% <0.001
Subcutaneous fat area (mm2) 34825 ± 10493 25005 ± 9146 −28% <0.001
Abdominal visceral fat area (mm2) 47469 ± 6344 41413 ± 7751 −13% <0.001
Epicardial adipose tissue thickness (mm)
Basal short axis plane
SIVG 10.0 ± 3.4 6.4 ± 2.2 −34% <0.001
IIVG 10.5 ± 4.7 6.3 ± 2.3 −31% <0.001
RVFW 6.8 ± 1.9 4.4 ± 1.3 −33% <0.001
Horizontal long axis plane
RAVG 16.7 ± 3.5 13.2 ± 2.3 −18% <0.001
LAVG 15.5 ± 3.8 10.3 ± 3.1 −32% <0.001
AIVG 9.2 ± 2.4 6.6 ± 1.5 −24% <0.001
AIVG: anterior interventricular groove; IIVG: inferior interventricular groove; LAVG: left atrioventricular groove; RAVG: right atrioventricular groove; RVFW: right
ventricular free wall; SIVG: superior interventricular groove.
*Percentage of changes = (after - before)/before weight loss, mean value.
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p = 0.005). The correlation between decrement ratio of
SIVG EAT and the decrement ratio of OGTT insulin
AUC was fair but not reaching statistical significance
(r =0.327, p = 0.095). Moreover, there was no correl-
ation between absolute difference of MR measured left
ventricular ejection fraction vs. HOMA-IR (r = −0.035,
p = 0.863) or OGTT-derived Matsuda ISI (r =0.067, p =
0.742) changes after weight loss.
Multivariate linear regression analysis of independent
variables correlated with percentage changes of HOMA-IR
index in obese non-diabetic men with MetS after weight
loss
In a multivariate linear regression analysis, the decrement
ratio of circulating leptin and SIVG EAT were independ-
ent variables correlated with improvements of HOMA-IR
index after weight loss, while changes in subcutaneous or
abdominal visceral fat were not (Table 4).
Multivariate linear regression analysis of independent
variables correlated with percentage changes of Matsuda
insulin-sensitivity index in obese non-diabetic men with
MetS after weight loss
In a multivariate linear regression analysis, the decrement
ratio of SIVG EAT thickness (r = −0.370, p = 0.017) and
subcutaneous fat area (r = −0.673, p = 0.006) were inde-
pendent variables correlated with the increment ratio of
OGTT-derived Matsuda ISI after weight loss (Table 5).
Discussion
The results of this study demonstrated that the decre-
ment ratio of SIVG EAT correlated with improvement ofboth HOMA-IR and OGTT-derived Matsuda insulin-
sensitivity indexes after weight loss in obese non-diabetic
men with MetS. In this study, we applied a weight loss
intervention to investigate its impact on changes of insulin-
resistance in non-diabetic obese men and extended the in-
vestigation parameters beyond subcutaneous or abdominal
visceral fat to regional EAT changes.
A previous report by Iacobellis et al. [43] showed that
EAT thickness measured by echocardiogram over the
right ventricle free wall was significantly correlated with
IR index in obese subjects. Manco et al. [44] reported that
MRI-measured EAT volume was a useful predictor for
HOMA-IR in obese children. Our study further corrobo-
rated the association of EAT with IR, and revealed a novel
finding showing that MRI-measured regional SIVG EAT
thickness change was independently associated with im-
provement of IR after weight loss in obese non-diabetic
men with MetS. Moreover, we used multiple IR indexes,
including the HOMA-IR and Matsuda ISI to validate the
association between SIVG EAT and IR changes.
EAT is metabolically active visceral fat that produces
inflammatory cytokines and adipokines, including leptin
[13,14,19]. Some studies have addressed the possible role
of EAT in coronary atherosclerosis, such as an increase
of local EAT leptin [19,20], and inflammatory cytokine
secretion [13], or a decrease of adiponectin production
[14], which might directly be diffused into adjacent cor-
onary circulation and influence atherosclerosis. Subjects
with MetS or coronary heart disease have been reported
to have higher leptin expression in EAT [19,20]. Beyond
the local production of leptin in EAT, there was also in-
creased circulating leptin levels in obesity, metabolic
syndrome, and IR state [25,45]. Weight loss decreased
Table 3 Univariate correlation analysis of *percentage changes of fasting HOMA-IR and OGTT-derived insulin-sensitivity
index (Matsuda) with *percentage changes of obesity-associated inflammatory markers, adipokines and MRI measured fat
index (study subjects: 27 obese non-diabetic men with metabolic syndrome, with weight loss >5%)
Factors (*percentage changes) HOMA-IR ISI-Matsuda
Correlation coefficients (r) p Correlation coefficients (r) p
BMI 0.201 0.314 −0.485 0.010
MR measured fat index
waist −0.014 0.944 −0.434 0.024
Subcutaneous fat area 0.216 0.280 −0.642 <0.001
Abdominal visceral fat area 0.094 0.641 −0.369 0.058
Epicardial adipose tissue thickness
Basal short axis plane
SIVG 0.408 0.035 −0.501 0.008
IIVG 0.259 0.193 −0.359 0.066
RVFW 0.342 0.080 −0.201 0.314
Horizontal long axis plane
RAVG −0.049 0.808 −0.213 0.287
LAVG −0.064 0.753 −0191 0.340
AIVG 0.018 0.929 −0.198 0.321
HDL-C −0.001 0.995 0.195 0.329
Triglyceride 0.037 0.856 −0.234 0.240
MCP-1 −0.164 0.414 0.050 0.803
HsCRP −0.003 0.989 −0.022 0.911
Adipokines
Adiponectin 0.093 0.643 0.269 0.175
Leptin 0.685 <0.001 −0.439 0.022
PAI −0.028 0.888 −0.176 0.379
AIVG: anterior interventricular groove; BMI (kg/m2): body mass index = body weight (kg)/height2 (m); HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostasis
model assessment of insulin resistance, defined as glucose mg/dl × insulin μU/mL/405; Hs-CRP: high sensitivity C-reactive protein; IIVG: inferior interventricular groove;
LAVG: left atrioventricular groove; MCP-1: monocyte chemotactic protein-1; Oral glucose tolerance test (OGTT)-derived insulin-sensitivity index (ISI), Matsuda: 10,000/sqrt
(FBG × FPI × G × I), where FPG is fasting glucose (mM), FPI is fasting insulin (μIU/ml), G is mean glucose (mM), I is mean insulin (μIU/ml) during the OGTT; PAI-1:
plasminogen activator protein-1; RAVG: right atrioventricular groove; RVFW: right ventricular free wall; SIVG: superior interventricular groove.
*Percentage of changes = (after - before)/before weight loss.
Table 4 Multivariate linear regression analysis of variables
related with percentage of changes of HOMA-IR index in
obese non-diabetic men with metabolic syndrome after
weight loss >5% (N = 27)
Predictor (*percentage of changes) Standardized
coefficient β
p
Subcutaneous fat area 0.090 0.609
Abdominal visceral fat area −0.148 0.408
SIVG EAT thickness 0.322 0.044
Leptin 0.626 <0.001
Dependent variable: percentage changes of HOMA-IR.
EAT: epicardial adipose tissue.
SIVG: superior interventricular groove.
HOMA-IR: homeostasis model assessment (HOMA) of insulin resistance = (fasting
glucose mg/dl × fasting insulin μU/mL)/405.
*Percentage of changes = (after - before)/before weight loss.
Table 5 Multivariate linear regression analysis of variables
related with percentage of changes of OGTT-derived
insulin-sensitivity Matsuda index, in obese non-diabetic men
with metabolic syndrome with weight loss >5% (N= 27)
Predictor (*percentage of changes) Standardized
coefficient β
p
Body mass index 0.194 0.458
Subcutaneous fat area −0.673 0.006
Abdominal visceral fat area 0.030 0.877
SIVG EAT thickness −0.370 0.017
Leptin −0.269 0.065
Dependent variable: percentage changes of Matsuda index.
EAT: epicardial adipose tissue.
SIVG: superior interventricular groove.
OGTT-derived insulin-sensitivity index (Matsuda): 10,000⁄sqrt (FBG × FPI × G × I)
where FPG is fasting glucose (mM), FPI is fasting insulin (μIU/ml), G is mean glucose
(mM), I is mean insulin (μIU/ml) during the OGTT.
*Percentage of changes = (after - before)/before weight loss.
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with changes of leptin after weight reduction in obese
children [45-47]. Our study further confirmed that the
decrement ratio of secretory leptin was independently
associated with improvement of HOMA-IR after weight
loss in obese non-diabetic men with MetS. In contrast,
other adipokines such as, adiponectin or PAI-1 changes
did not correlate well with improvement of HOMA-IR.
EAT surrounding the thin-walled coronary veins may
exert greater systemic effects by diffusion of its small
metabolically active molecules into the circulation [10,18].
The great cardiac vein traverses the anterior inter-ventricular
groove and is embedded by a substantial amount of EAT.
Given the amount of fat around and the presence of a lar-
ger drainage territories of the anterior wall of the heart
into the great cardiac vein, this may partly explain why
only changes of EAT thickness in the SIVG was associated
with the IR changes after weight loss in obese men with
MetS [10,18].
In our study, the decrement ratio of subcutaneous fat
rather than abdominal visceral fat correlated with im-
provement of Matsuda ISI after weight loss in obese
non-diabetic men with MetS. The decrement ratio of ab-
dominal visceral fat was neither correlated with changes
of HOMA-IR or ISI-Matusda after weight loss in this
study. A previous report by Klein et al. [27] showed that
liposuction of subcutaneous fat did not alter the insulin-
sensitivity, or circulating hs-CRP or adiponectin in obese
women. However, Kremen et al. [48] found that both sub-
cutaneous and EAT were sources of pro-inflammatory cy-
tokines in cardiac surgery patients and may contribute to
the development of postoperative insulin resistance. An-
other report analyzing local fat sample from subjects
undergoing coronary bypass surgery showed that EAT
produced more inflammatory molecules than subcutane-
ous adipose tissue [13]. In addition, studies by Grundy
et al. also showed that subcutaneous truncal fat played a
major role in obesity-related insulin resistance in men,
whereas intraperitoneal fat and retroperitoneal fat had a
lesser role [30,31]. Kaess et al. [49] proposed visceral fat
vs. subcutaneous fat ratio as a better correlate of cardio-
metabolic risk, above and beyond BMI and visceral fat
alone. These discrepancies may be caused by different eth-
nic groups, gender, and the methods employed. Certainly,
further studies are required to investigate the changes in
subcutaneous or abdominal visceral fat with improvement
of IR after weight reduction.
Whether different regional EAT or changes of EAT
thickness participate in mechanisms leading to different
inflammatory or metabolic risks requires further in vitro
and in vivo investigations [18,19,23]. This study only ob-
served a useful surrogate EAT parameter (SIVG thickness)
change for indicating the improvement of insulin-resistance
after weight loss in obese men with MetS. However, thepathogenesis underlying the close correlations between
changes of regional EAT and circulating leptin with the
improvement of IR after weight loss in obese MetS de-
mands further in vivo animal studies and in vitro cell sig-
naling pathway investigations [19]. This study recruited
obese men only and the results might not be applicable to
women. The major limitation of the study was small
sample size and the results were mainly from clinical data
analysis without mechanism investigations. Moreover, this
result was a post-hoc subgroup analysis of an original 40
men who participated in a weight loss study by diet and
exercise. Among them, only 32 agreed MRI exam. And of
whom, a subgroup who had achieved weight loss >5% was
entered into analysis for correlation between regional fat
change and IR. The potential bias resulted from post hoc
subgroup analysis could not be neglected.
In conclusion, the decrement ratio of SIVG EAT thick-
ness was independently associated with improvement of IR
index after weight loss in obese non-diabetic men with
MetS. The underlying mechanisms linking change in SIVG
EAT thickness and improvement of systemic IR require
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